4.8 Article

NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus

Journal

FRONTIERS IN IMMUNOLOGY
Volume 7, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2016.00607

Keywords

Epstein-Barr virus; NKG2A; NK cells; B cells; lymphoblastoid cell lines

Categories

Funding

  1. NIH/NIGMS IRACDA grant
  2. Transplant and Tissue Engineering Center of Excellence
  3. NSF training grant [DGE-114740]
  4. Ruth L. Kirschstein National Research Service Award [1F31AI118469-01]
  5. NIH [DP2AI11219301, AI113130, AI115313, AI104230]

Ask authors/readers for more resources

Epstein-Barr virus (EBV) is a human.-herpesvirus that establishes latency and lifelong infection in host B cells while achieving a balance with the host immune response. When the immune system is perturbed through immunosuppression or immunodeficiency, however, these latently infected B cells can give rise to aggressive B cell lymphomas. Natural killer (NK) cells are regarded as critical in the early immune response to viral infection, but their role in controlling expansion of infected B cells is not understood. Here, we report that NK cells from healthy human donors display increased killing of autologous B lymphoblastoid cell lines (LCLs) harboring latent EBV compared to primary B cells. Coculture of NK cells with autologous EBV+ LCL identifies an NK cell population that produces IFN gamma and mobilizes the cytotoxic granule protein CD107a. Multi-parameter flow cytometry and Boolean analysis reveal that these functional cells are enriched for expression of the NK cell receptor NKG2A. Further, NKG2A(+) NK cells more efficiently lyse autologous LCL than do NKG2A(-) NK cells. More specifically, NKG2A(+) 2B4(+) CD16(-)CD57(-)NKG2C(-)NKG2D(+) cells constitute the predominant NK cell population that responds to latently infected autologous EBV+ B cells. Thus, a subset of NK cells is enhanced for the ability to recognize and eliminate autologous, EBV-infected transformed cells, laying the groundwork for harnessing this subset for therapeutic use in EBV+ malignancies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available